ReviewInternational journal of clinical oncology2026
Subsite- and histology-specific epidemiology of head and neck cancers in Japan from 2016 to 2019: an application of a new classification of rare cancers.
Review in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHead and neck cancers comprise multiple anatomical sites. Due to their rarity, previous studies have often aggregated anatomically or histologically distinct cancers or excluded rare entities altogether. Moreover, the list of head and neck cancer entities has evolved along with the adoption of new pathological insights.
methodsIn our previous study, we proposed a new classification of rare cancers, based on the International Classification of Diseases for Oncology 3.2 coding system, using data from cancer patients at all sites recorded in the National Cancer Registry of Japan. In this study, we created a comprehensive list of head and neck cancers to improve the accuracy of epidemiological reporting using population-based data from 2016 to 2019. Lymphoid diseases were excluded, and only epithelial tumors and sarcomas were included in the analysis.
resultsIn Japan, head and neck cancer accounts for approximately 30,000 cases annually, accounting for 2.9% of all cancer cases. The incidence of squamous cell carcinoma arising from the oral cavity and lip was 7.5 cases per 100,000 per year, which does not meet the criterion for a rare cancer. Other head and neck cancers were rare. The most frequent sites were the oral cavity and lip, followed by the larynx, hypopharynx, and oropharynx. The annual number of cases increased during the study period.
conclusionMost head and neck cancers were rare during the study period. This result highlights the importance of continued efforts to track incidence trends in parallel with evolving pathological definitions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.